These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19255602)

  • 41. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome.
    Chatterjee B; Suri J; Suri JC; Mittal P; Adhikari T
    Sleep Med; 2014 Dec; 15(12):1547-53. PubMed ID: 25311833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
    González F
    Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
    Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
    Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and management of polycystic ovary syndrome: a practical guide.
    Stankiewicz M; Norman R
    Drugs; 2006; 66(7):903-12. PubMed ID: 16740005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.
    Lambrinoudaki I
    Maturitas; 2011 Jan; 68(1):13-6. PubMed ID: 20943333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
    Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Body composition and polycystic ovary syndrome].
    Zabuliene L; Tutkuviene J
    Medicina (Kaunas); 2010; 46(2):142-57. PubMed ID: 20440089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy.
    Spinedi E; Cardinali DP
    Int J Endocrinol; 2018; 2018():1349868. PubMed ID: 30147722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
    Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
    Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polycystic Ovary Syndrome, Obesity, and Pregnancy.
    Joham AE; Palomba S; Hart R
    Semin Reprod Med; 2016 Mar; 34(2):93-101. PubMed ID: 26854709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diabetes, Polycystic Ovarian Syndrome, Obstructive Sleep Apnea, and Obesity: A Systematic Review and Important Emerging Themes.
    Bambhroliya Z; Sandrugu J; Lowe M; Okunlola O; Raza S; Osasan S; Sethia S; Batool T; Hamid P
    Cureus; 2022 Jun; 14(6):e26325. PubMed ID: 35911341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil.
    Maffazioli GDN; Lopes CP; Heinrich-Oliveira V; Lobo RA; Hayashida SAY; Soares JM; Maciel GAR; Baracat EC
    Int J Gynaecol Obstet; 2020 Dec; 151(3):383-391. PubMed ID: 32931592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of low-grade inflammation in the polycystic ovary syndrome.
    Repaci A; Gambineri A; Pasquali R
    Mol Cell Endocrinol; 2011 Mar; 335(1):30-41. PubMed ID: 20708064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polycystic ovary syndrome and metabolic syndrome.
    Ali AT
    Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.